Bright Minds Biosciences (DRUG) Competitors $83.50 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$83.44 -0.06 (-0.08%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. MOR, ALMS, BEAM, DYN, and TARSShould you buy Bright Minds Biosciences stock or one of its competitors? MarketBeat compares Bright Minds Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bright Minds Biosciences include MorphoSys (MOR), Alumis (ALMS), Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. DRUG vs. MORDRUG vs. ALMSDRUG vs. BEAMDRUG vs. DYNDRUG vs. TARSHow does Bright Minds Biosciences compare to MorphoSys?Bright Minds Biosciences (NASDAQ:DRUG) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Which has more risk & volatility, DRUG or MOR? Bright Minds Biosciences has a beta of -5.35, suggesting that its stock price is 635% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Which has preferable valuation and earnings, DRUG or MOR? Bright Minds Biosciences has higher earnings, but lower revenue than MorphoSys. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$8.74M-$2.44N/AMorphoSys$238.28M11.99-$205.35M-$3.48N/A Does the media prefer DRUG or MOR? In the previous week, Bright Minds Biosciences had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Bright Minds Biosciences and 0 mentions for MorphoSys. Bright Minds Biosciences' average media sentiment score of 2.04 beat MorphoSys' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Overall Sentiment Bright Minds Biosciences Very Positive MorphoSys Neutral Do institutionals and insiders have more ownership in DRUG or MOR? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is DRUG or MOR more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Bright Minds Biosciences' return on equity of -20.58% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -20.58% -20.25% MorphoSys -226.79%-694.31%-22.55% Do analysts recommend DRUG or MOR? Bright Minds Biosciences currently has a consensus price target of $143.83, suggesting a potential upside of 72.26%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bright Minds Biosciences is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBright Minds Biosciences beats MorphoSys on 12 of the 14 factors compared between the two stocks.How does Bright Minds Biosciences compare to Alumis?Alumis (NASDAQ:ALMS) and Bright Minds Biosciences (NASDAQ:DRUG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk. Does the media favor ALMS or DRUG? In the previous week, Alumis had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 11 mentions for Alumis and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 2.04 beat Alumis' score of 0.90 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk and volatility, ALMS or DRUG? Alumis has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.35, suggesting that its share price is 635% less volatile than the broader market. Do analysts prefer ALMS or DRUG? Alumis presently has a consensus target price of $40.30, suggesting a potential upside of 83.02%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 72.26%. Given Alumis' higher possible upside, equities research analysts plainly believe Alumis is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has stronger valuation & earnings, ALMS or DRUG? Bright Minds Biosciences has lower revenue, but higher earnings than Alumis. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumis$24.05M116.73-$243.32M-$1.98N/ABright Minds BiosciencesN/AN/A-$8.74M-$2.44N/A Do insiders & institutionals have more ownership in ALMS or DRUG? 40.5% of Bright Minds Biosciences shares are held by institutional investors. 40.7% of Alumis shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is ALMS or DRUG more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Bright Minds Biosciences' return on equity of -20.58% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Alumis-2,825.70% -88.79% -70.72% Bright Minds Biosciences N/A -20.58%-20.25% SummaryBright Minds Biosciences beats Alumis on 8 of the 15 factors compared between the two stocks.How does Bright Minds Biosciences compare to Beam Therapeutics?Bright Minds Biosciences (NASDAQ:DRUG) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Which has more risk and volatility, DRUG or BEAM? Bright Minds Biosciences has a beta of -5.35, suggesting that its share price is 635% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market. Does the media refer more to DRUG or BEAM? In the previous week, Beam Therapeutics had 5 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Beam Therapeutics and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 2.04 beat Beam Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Beam Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend DRUG or BEAM? Bright Minds Biosciences presently has a consensus price target of $143.83, suggesting a potential upside of 72.26%. Beam Therapeutics has a consensus price target of $46.83, suggesting a potential upside of 63.52%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Beam Therapeutics 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.71 Do insiders and institutionals hold more shares of DRUG or BEAM? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is DRUG or BEAM more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Bright Minds Biosciences' return on equity of -20.58% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -20.58% -20.25% Beam Therapeutics -39.66%-29.00%-22.61% Which has higher earnings & valuation, DRUG or BEAM? Bright Minds Biosciences has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$8.74M-$2.44N/ABeam Therapeutics$139.74M21.09-$79.99M-$0.68N/A SummaryBright Minds Biosciences beats Beam Therapeutics on 8 of the 15 factors compared between the two stocks.How does Bright Minds Biosciences compare to Dyne Therapeutics?Dyne Therapeutics (NASDAQ:DYN) and Bright Minds Biosciences (NASDAQ:DRUG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends. Do analysts recommend DYN or DRUG? Dyne Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 101.50%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 72.26%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Dyne Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 2.94Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is DYN or DRUG more profitable? Bright Minds Biosciences' return on equity of -20.58% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -58.28% -46.77% Bright Minds Biosciences N/A -20.58%-20.25% Does the media favor DYN or DRUG? In the previous week, Dyne Therapeutics had 10 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 12 mentions for Dyne Therapeutics and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 2.04 beat Dyne Therapeutics' score of 0.83 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher valuation & earnings, DYN or DRUG? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$446.21M-$3.22N/ABright Minds BiosciencesN/AN/A-$8.74M-$2.44N/A Do insiders & institutionals have more ownership in DYN or DRUG? 96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, DYN or DRUG? Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.35, indicating that its share price is 635% less volatile than the broader market. SummaryDyne Therapeutics beats Bright Minds Biosciences on 7 of the 13 factors compared between the two stocks.How does Bright Minds Biosciences compare to Tarsus Pharmaceuticals?Bright Minds Biosciences (NASDAQ:DRUG) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings. Do analysts rate DRUG or TARS? Bright Minds Biosciences currently has a consensus price target of $143.83, indicating a potential upside of 72.26%. Tarsus Pharmaceuticals has a consensus price target of $90.67, indicating a potential upside of 45.63%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Bright Minds Biosciences is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Tarsus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.78 Which has more volatility and risk, DRUG or TARS? Bright Minds Biosciences has a beta of -5.35, meaning that its share price is 635% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Which has stronger earnings and valuation, DRUG or TARS? Bright Minds Biosciences has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$8.74M-$2.44N/ATarsus Pharmaceuticals$451.36M5.93-$66.42M-$1.14N/A Is DRUG or TARS more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Bright Minds Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -20.58% -20.25% Tarsus Pharmaceuticals -9.02%-14.19%-8.89% Does the media refer more to DRUG or TARS? In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 2.04 beat Tarsus Pharmaceuticals' score of 0.70 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tarsus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in DRUG or TARS? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryTarsus Pharmaceuticals beats Bright Minds Biosciences on 8 of the 15 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition ExportMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$812.64M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E RatioN/A10.3417.9322.89Price / SalesN/A323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book3.617.0910.377.14Net Income-$8.74M$24.45M$3.57B$335.98M7 Day Performance11.33%5.45%6.01%3.56%1 Month Performance-6.35%2.43%3.52%2.54%1 Year Performance187.83%62.98%34.13%35.05% Bright Minds Biosciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences3.2384 of 5 stars$83.50flat$143.83+72.3%+187.8%$812.64MN/AN/AN/APositive NewsEarnings ReportMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28MN/A730News CoverageALMSAlumis3.7562 of 5 stars$21.84+3.3%$40.30+84.5%+351.2%$2.78B$24.05MN/AN/ABEAMBeam Therapeutics3.2737 of 5 stars$26.48-1.2%$46.83+76.9%+70.2%$2.72B$139.74MN/A510Gap DownDYNDyne Therapeutics3.6023 of 5 stars$16.30-1.4%$35.00+114.7%+48.6%$2.69BN/AN/A100 Related Companies and Tools Related Companies MorphoSys Competitors Alumis Competitors Beam Therapeutics Competitors Dyne Therapeutics Competitors Tarsus Pharmaceuticals Competitors Structure Therapeutics Competitors IDEAYA Biosciences Competitors Disc Medicine Competitors Relay Therapeutics Competitors Arcutis Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
